- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
CELG
Celgene Corporation Looks Cheap, Considering Its Potential
For some time, Celgene stock has been a great performer. But this changed significantly during the past six months as Celgene suffered some major blows. The potential for CELG is still there, so this presents a nice opportunity for investors in Celgene stock.
Despite Struggles Celgene Corporation Stock Is Still A Buy
Despite the drop, Celgene stock is a huge bargain. Revenues are still strong and there is still lots of time for CELG to develop other profitable drugs before REVLIMID falls off the patent cliff.
Celgene (CELG) a Strong Sell at $91.56
Celgene (CELG) a Strong Sell this week based on the most recent stock market rankings, and comparative pricing of its shares.
This week, Celgene (CELG) a Strong Sell
At $89.04, Celgene (CELG) a Strong Sell based on the most recent relative pricing of its shares and market intelligence.
At $87.12, Celgene (CELG) a Sell
Celgene (CELG) a Sell this week based on the most current analysis, and relative pricing of its shares.
Celgene Corporation Stock Sinks on MS Drug Missteps
Celgene (CELG) stock was down Wednesday on news of troubles with the New Drug Application for multiple sclerosis (MS) drugs ozanimod.
3 Stocks to Watch on Wednesday: Celgene Corporation (CELG), e.l.f. Beauty Inc (ELF) and Express Scripts Holding Company (ESRX)
Celgene's (CELG) drug application is turned down by FDA, e.l.f. Beauty (ELF) misses revenue outlook and Express Scripts (ESRX) earnings beat estimates.
At $96.14, Celgene (CELG) a Sell
Celgene (CELG) remains a Sell this week based on the most current comparative pricing of its shares and stock market rankings.
You Definitely Should Buy Celgene Corporation Stock After Earnings Beat
Celgene shares have traded mixed since reporting earnings. However, management told a reassuring story and CELG stock is one to buy at these levels.
Trade of the Day: Celgene Corporation Is a Catch-Up Play
CELG stock continues to notably lag some of its peers in the biotechnology group, but this could soon change and set up a juicy Celgene trade.
Why Investors Should Stay Long Eli Lilly and Co Stock
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being.
Juno Therapeutics (JUNO) Shares Skyrocket on Celgene Buyout
Juno Therapeutics (JUNO) shares were soaring as the company has completed a deal with Celgene (CELG) that will see the latter buy the former for $9 billion.
Why Celgene Corporation Stock Is ALL About the Buyouts
For CELG stock, traders are going focus on its pipeline and nothing else. With that in mind, here's what Celgene's longer-term prospects look like.
The Index Charts Turn Parabolic
I want to continue respecting strong stock up-trends such as the QQQ, but should point out that that in my eye we are getting very stretched.
Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive
Celgene faces big risks in buying cancer drug candidates. The drug may fail late tests, or it might not get its price past insurers.
No Reason To Rush Into Juno Therapeutics Inc Stock After This Big Pop
Celgene will very likely acquire Juno for somewhere north of $70 per share, but Juno stock is already priced accordingly.